Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Adicet Bio Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ACET
Nasdaq
8731
https://www.adicetbio.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Adicet Bio Inc
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Dec 30th, 2022 9:43 pm
Shareholders in Adicet Bio (NASDAQ:ACET) have lost 49%, as stock drops 22% this past week
- Dec 20th, 2022 1:23 pm
Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)
- Dec 10th, 2022 3:00 pm
Adicet Bio to Host Investor Webcast to Discuss Updated Clinical Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)
- Dec 2nd, 2022 12:00 pm
Adicet Bio to Present at the Virtual JMP Securities Hematology and Oncology Summit
- Nov 30th, 2022 9:00 pm
Adicet Bio Appoints Nancy Boman, M.D., Ph.D., as Senior Vice President and Chief Regulatory Officer
- Nov 29th, 2022 12:00 pm
Adicet Bio Third Quarter 2022 Earnings: US$0.53 loss per share (vs US$0.44 loss in 3Q 2021)
- Nov 11th, 2022 10:24 am
Adicet Reports Third Quarter 2022 Financial Results and Provides Business Updates
- Nov 8th, 2022 9:10 pm
Adicet Bio Showcases Preclinical Data for Four New Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
- Nov 7th, 2022 1:00 pm
Adicet Bio Reports ASH Abstract Data from Ongoing ADI-001 Phase 1 Trial in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)
- Nov 3rd, 2022 1:00 pm
Adicet Bio to Present at the 2022 Jefferies London Healthcare Conference
- Nov 1st, 2022 11:00 am
Calculating The Intrinsic Value Of Adicet Bio, Inc. (NASDAQ:ACET)
- Oct 23rd, 2022 12:39 pm
Adicet Bio to Present Preclinical Data from Allogeneic Gamma Delta T Cell Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
- Oct 5th, 2022 12:00 pm
We're Hopeful That Adicet Bio (NASDAQ:ACET) Will Use Its Cash Wisely
- Sep 26th, 2022 10:26 am
Adicet Bio to Present at Upcoming Investor Conferences
- Sep 7th, 2022 8:10 pm
The Consensus EPS Estimates For Adicet Bio, Inc. (NASDAQ:ACET) Just Fell Dramatically
- Aug 16th, 2022 10:16 am
Adicet Reports Second Quarter 2022 Financial Results and Provides Business Updates
- Aug 10th, 2022 11:00 am
Adicet Bio Reports Emerging Data from ADI-001 Phase 1 Trial at the American Society of Clinical Oncology Annual Meeting
- Jun 6th, 2022 11:00 am
Adicet Bio Reports Positive Clinical Update from ADI-001 Phase 1 Trial in Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL)
- May 26th, 2022 9:00 pm
Results: Adicet Bio, Inc. Confounded Analyst Expectations With A Surprise Profit
- May 15th, 2022 12:21 pm
Scroll